Isomorphic Labs Eyes $2B+ in Major New Funding Round

Isomorphic Labs, the AI-powered drug discovery company spun out of Google DeepMind, is in advanced discussions to raise more than $2 billion in a new funding round, according to people familiar with the matter. The deal, expected to be led by Thrive Capital — the same venture firm that spearheaded the company's inaugural round last year — would mark one of the largest private raises in the AI-for-biotech space to date, with parent company Alphabet also set to participate.

The massive fundraise underscores the growing conviction among top-tier investors that AI-driven drug development represents one of the most commercially significant applications of artificial intelligence, potentially rivaling the generative AI boom that has dominated headlines over the past 2 years.

Key Facts at a Glance

• Isomorphic Labs is seeking to raise over $2 billion in its latest funding round
• Thrive Capital is expected to lead the round, reprising its role from the company's first fundraise
• Alphabet, Google's parent company, will also participate as an investor
• The company was spun out of Google DeepMind, leveraging breakthrough AI research in protein structure prediction
• This round would make Isomorphic Labs one of the best-funded AI drug discovery startups globally
• The funding talks are described as being in advanced stages

Thrive Capital Doubles Down on AI Drug Discovery

Thrive Capital's decision to lead a second consecutive round in Isomorphic Labs signals deep confidence in the company's trajectory. The New York-based venture firm, founded by Joshua Kushner, has become one of the most influential investors in the AI ecosystem, with notable positions in companies like OpenAI and various AI infrastructure startups.

By leading both the initial and follow-on rounds, Thrive Capital is making a bold bet that Isomorphic Labs can translate DeepMind's groundbreaking scientific achievements into commercially viable pharmaceutical products. This is no small wager — drug development typically requires billions of dollars and decades of research before generating meaningful revenue.

Alphabet's continued participation also speaks volumes. The tech giant has historically been selective about which spinoffs and subsidiaries receive direct investment beyond their initial incubation phase. The company's willingness to invest alongside external venture capital suggests that Isomorphic Labs has demonstrated meaningful progress in its pipeline and platform capabilities.

From AlphaFold to Drug Pipelines: The DeepMind Connection

Isomorphic Labs traces its origins directly to one of the most celebrated achievements in modern AI research: AlphaFold. Developed by Google DeepMind, AlphaFold solved the decades-old problem of predicting protein structures from amino acid sequences — a breakthrough that earned DeepMind co-founder Demis Hassabis and researcher John Jumper the 2024 Nobel Prize in Chemistry.

The company was founded in 2021 with a mission to apply these same AI techniques to the drug discovery process. Rather than simply predicting protein structures, Isomorphic Labs aims to use AI to understand the fundamental mechanisms of biology and design novel therapeutic molecules.

This approach differs significantly from traditional pharmaceutical research, which often relies on trial-and-error experimentation that can take 10 to 15 years and cost upwards of $2.6 billion per approved drug. Key areas where Isomorphic Labs applies AI include:

• Target identification: Using AI to pinpoint disease-relevant biological targets
• Molecular design: Generating novel drug candidates computationally
• Binding prediction: Forecasting how molecules interact with biological targets
• Toxicity screening: Predicting adverse effects before expensive lab testing
• Clinical trial optimization: Improving patient selection and trial design through data analysis

How Isomorphic Labs Compares to Competitors

The AI drug discovery space has become increasingly crowded, with dozens of startups and established pharma companies racing to integrate machine learning into their R&D pipelines. However, Isomorphic Labs occupies a unique position due to its direct lineage from DeepMind's research capabilities.

Compared to competitors like Recursion Pharmaceuticals (which went public via a $436 million IPO in 2021) or Insilico Medicine (which raised $95 million in its Series D), Isomorphic Labs' potential $2 billion raise would dwarf typical funding levels in the sector. Even Xaira Therapeutics, which launched in 2024 with a remarkable $1 billion in initial funding, would be surpassed by this round.

The funding differential reflects several competitive advantages that Isomorphic Labs holds:

• Direct access to DeepMind's AI research and talent pipeline
• Proprietary models built on top of AlphaFold's architecture
• Alphabet's computational infrastructure, including access to Google's TPU chips
• Strategic partnerships with major pharmaceutical companies
• Nobel Prize-validated science underpinning the core technology

This combination of scientific credibility, computational resources, and financial backing creates a moat that few competitors can match. The $2 billion raise would further extend this advantage, allowing Isomorphic Labs to pursue multiple drug programs simultaneously.

The Broader AI-Pharma Investment Boom

Isomorphic Labs' fundraise comes amid a broader surge of investment into AI applications for healthcare and pharmaceuticals. The convergence of improved AI models, cheaper compute, and growing datasets has convinced investors that the technology is finally ready to transform one of the world's largest and most complex industries.

Global pharmaceutical R&D spending exceeded $250 billion in 2024, yet the industry continues to struggle with declining productivity — fewer approved drugs per dollar invested. AI promises to reverse this trend by dramatically reducing the time and cost of bringing new therapies to market.

Major pharmaceutical companies have taken notice. Eli Lilly, Novartis, and Sanofi have all signed significant AI partnerships in recent years. Isomorphic Labs itself has reportedly entered into deals with major pharma players, though the specific terms and partners have not been fully disclosed.

The venture capital community has responded accordingly. According to industry data, AI-biotech startups raised more than $5 billion globally in 2024, a figure that 2025 is on pace to exceed significantly — especially if Isomorphic Labs closes its $2 billion round.

What This Means for the AI Industry

The Isomorphic Labs fundraise carries implications that extend well beyond the pharmaceutical sector. It represents a maturation of the AI investment thesis — moving from foundation models and chatbots to deeply vertical applications that tackle specific, high-value problems.

For the broader tech industry, several key takeaways emerge. First, AI's value proposition is shifting from general-purpose tools to domain-specific solutions. While companies like OpenAI and Anthropic build horizontal platforms, Isomorphic Labs exemplifies the vertical approach — applying cutting-edge AI to a single, enormously valuable domain.

Second, the deal highlights Alphabet's evolving AI strategy. By maintaining investment in Isomorphic Labs as a separate entity rather than keeping it within DeepMind, Google is signaling that some AI applications are better pursued through independent, commercially focused organizations rather than within a research lab.

Third, the round demonstrates that investors remain willing to write enormous checks for AI companies with credible paths to transformative outcomes, even in a market that has grown more cautious about AI hype in general.

Looking Ahead: Timeline and Expectations

If the $2 billion round closes as expected, Isomorphic Labs will have significant resources to accelerate its drug discovery programs. Industry observers expect the company to advance multiple candidates into preclinical and early clinical stages over the next 2 to 3 years.

The critical question remains whether AI-designed drugs can succeed in clinical trials at higher rates than traditionally developed compounds. The pharmaceutical industry's historical success rate — roughly 90% of drugs fail in clinical trials — sets a high bar for improvement. If Isomorphic Labs can demonstrate even a modest improvement in this success rate, the economic implications would be staggering.

Longer term, the company could pursue an IPO, though the current timeline for such a move remains unclear. With $2 billion in fresh capital and Alphabet's backing, Isomorphic Labs has the luxury of remaining private while building out its pipeline.

What is clear is that the intersection of artificial intelligence and drug discovery has entered a new phase of investment intensity. Isomorphic Labs' fundraise is not just a milestone for one company — it is a signal that the smartest money in technology believes AI will fundamentally reshape how humanity develops medicines. The next few years will determine whether that conviction was justified.